Evidence map›Paper›PMID 41787404›Full record

ReviewCell communication and signaling : CCS2026

The NAT10/ac

Caiyun Shang, Xiaoxue Wang, Yanling Huang, Jingyi Zhu, Xueqian Liu, Heng Zhang, Wuxiang Guan, Haojie Hao, Fang Zhang

Abstract readReview
In one paragraph

Review in Cell communication and signaling : CCS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Caiyun Shang *School of Pharmacy, Hubei University of Chinese Medicine, Wuhan, Hubei, 430065, China.
Xiaoxue Wang *School of Pharmacy, Hubei University of Chinese Medicine, Wuhan, Hubei, 430065, China.
Yanling HuangCenter for Emerging Infectious Diseases, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, Hubei, 430071, China.
Jingyi ZhuHubei JiangXia Laboratory, Wuhan, Hubei, 430200, China.
Xueqian LiuHubei JiangXia Laboratory, Wuhan, Hubei, 430200, China.
Heng ZhangHubei JiangXia Laboratory, Wuhan, Hubei, 430200, China.
Wuxiang GuanCenter for Emerging Infectious Diseases, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, Hubei, 430071, China.
Haojie HaoCenter for Emerging Infectious Diseases, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, Hubei, 430071, China. haohj@wh.iov.cn.
Fang ZhangHubei JiangXia Laboratory, Wuhan, Hubei, 430200, China. zhangfang@hbjxlab.com.

Funding

Health Commission of Hubei Province scientific research project WJ2025M154Health Commission of Hubei Province scientific research project WJ2025M186Hubei Jiangxia Laboratory Biosafety Key R&D Project JXBS013Hubei Province Youth Science and Technology Talent Training Project 2025DJA084National Natural Science Foundation of China 32570183Natural Science Foundation of Hubei Province 2024AFB1065Natural Science Foundation of Hubei Province 2025AFB976the Open Research Fund of Hubei Jiangxia Laboratory 2025JXKF012
6 · The paper itself

Abstract

RNA modifications represent a fundamental layer of epitranscriptomic regulation. Among them, N4-acetylcytidine (ac4C)—a highly conserved and functionally versatile mark deposited by N-acetyltransferase 10 (NAT10)—has recently emerged as a critical coordinator of immunometabolic homeostasis. In this review, we synthesize current evidence establishing the NAT10/ac4C axis as a central signaling hub that integrates immune regulation and metabolic control through post-transcriptional modulation of key transcripts. We summarize mechanistic advances demonstrating how ac4C shapes innate and adaptive immunity—including macrophage polarization, T cell activation, and B cell responses—while concurrently directing metabolic programs across glucose, lipid, and amino acid pathways via effects on RNA stability and translation. We further highlight convergent immunometabolic mechanisms by which dysregulated NAT10/ac4C signaling drives diverse pathological states. In cancer, aberrant ac4C activity promotes tumor-intrinsic growth, immunosuppressive microenvironment remodeling, and metabolic rewiring. Similar NAT10-linked immunometabolic circuits underlie autoimmune diseases, sepsis, and metabolic inflammatory disorders. Finally, we evaluate the landscape of NAT10 inhibitors and discuss opportunities for mechanism-guided therapeutic exploration. Together, this review positions the NAT10/ac4C axis not merely as an RNA-modifying pathway, but as a dynamic, disease-relevant integrator at the intersection of epitranscriptomics, immunity, and metabolism.

Indexed as

CytidineDiseaseRNASignal TransductionAcetylationAnimalsEpitranscriptomeEpitranscriptomicsHumansN-Terminal AcetyltransferasesCytidineN-acetylcytidineNAT10 protein, humanN-Terminal AcetyltransferasesRNAImmune regulationMetabolic reprogrammingN 4-acetylcytidine (ac4C)NAT10RNA epitranscriptomicsTherapeutic targeting

Identifiers

PMID41787404
PMCPMC13088626

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.